Morgan Stanley reiterates Underweight on Progressive stock at $190 By Investing.com

Morgan Stanley reiterated Underweight on Progressive with a $190 price target, citing slower-than-expected policies in force growth, a disappointing attritional loss ratio, and questions around premium growth after calendar adjustments. The firm remains focused on how quickly the combined ratio normalizes higher, with inflation and rising competition as key risks. Offseting this, Q1 2026 net premiums written rose 6% to $23.64B and net income increased 10% to $2.82B, while buybacks and the combined ratio continue to support the stock.

Analysis

The message for PGR is less about near-term earnings quality and more about the shape of underwriting margin reversion. When growth is aided by timing adjustments, the market is effectively left to price the durability of the expense and loss ratio rather than the headline premium number, which creates a setup where the stock can look cheap on trailing metrics yet still de-rate if policy count momentum stays soft into the next two quarters. That asymmetry matters because insurers usually get the benefit of the doubt until the market concludes margin compression is structural, not cyclical.

The second-order risk is competitive intensity spilling into pricing discipline across personal auto. If a large carrier is prioritizing volume normalization over margin defense, peers can be forced into either matching share grabs or preserving profitability, and the latter usually means slower top-line growth for the group with delayed multiple expansion. That means the real loser may be the insurers that are most exposed to auto and least able to offset with investment income or specialty lines.

Contrarianly, the consensus may be overestimating how quickly buybacks can offset a slowing underwriting story. Repurchases support EPS mechanically, but if reserve adequacy, severity inflation, or rate competition worsen, the market will start capitalizing a lower terminal ROE, which is a more important driver than one quarter of buybacks. The key catalyst window is the next 1-3 months: if policy count trends improve seasonally and the combined ratio stabilizes, the bear case likely gets pushed out; if not, the name can stay range-bound despite ‘cheap’ valuation.

Key Decisions for Investors

• Short PGR on strength into earnings guidance updates; target 8-12% downside over 1-3 months if policy count softness persists and the market reprices terminal ROE lower.
• Pair trade: long a higher-quality P&C insurer with stronger specialty/less auto exposure vs short PGR; the spread should work if auto pricing remains competitive and underwriting leverage disappoints over the next 1-2 quarters.
• Sell upside calls on PGR for the next earnings cycle if shares rally toward analyst targets; the skew favors capped upside because buybacks can support the stock but not re-rate it without cleaner growth evidence.
• For event-driven traders, wait for confirmation of monthly policy count inflection before buying; if sequential policy growth improves for 2 consecutive months, a tactical long can work for a 5-7% rebound, but risk/reward is poor before that signal.
• Monitor peers with heavier auto exposure for spillover weakness; use any industry-wide bounce to trim longs in the more competitively exposed names rather than treating PGR as a standalone valuation story.